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Background
BAY 60-4552 is a direct soluble guanylate cyclase (sGC)
stimulator that acts independently of nitric oxide (NO).
In preclinical studies BAY 60-4552 exhibited potent
vasorelaxing properties and end-organ protective effects.
Secondary pulmonary hypertension is a determinant of
morbidity and mortality in patients with biventricular
heart failure (bivHF). Weassumed that BAY 60-4552
would improve cardiopulmonary hemodynamics by
restoring functionality of the NO/sGC/cGMP pathway
and be well tolerated in patients with bivHF.
Methods
This study evaluated safety, tolerability and invasive
hemodynamics of 1, 2.5, 5, 7.5 and 10 mg oral BAY 60-
4552 in patients with bivHF (LVEF ≤ 45%, mean pulmo-
nary artery pressure (mPAP) ≥ 25 mmHg, pulmonary cap-
illary wedge pressure [PCWP] ≥ 18 mmHg).
Results
31 male and 11 female patients (65 ± 11 years; BMI 27.4
± 4.4) were included. Mean hemodynamic parameters at
baseline were PCWP: 23.9 ± 4.5 mmHg; right atrial pres-
sure (RAP): 10.6 ± 4.3 mmHg; mPAP: 35.7 ± 8 mmHg;
systolic blood pressure (SBP): 119.2 ± 17.4 mmHg; sys-
temic vascular resistance (SVR): 1721 ± 534 dyn￿s￿cm-5;
heart rate (HR): 70.6 ± 11.2 bpm; and cardiac index (CI):
1.99 ± 0.48 L/min/m2. Table 1 summarizes peak changes
in invasive hemodynamics aftersingle dosesof 2.5, 7.5 and
10 mg. No relevant HR increase was observed. BAY 60-
4552 was safe and well tolerated with mild adverse events
(asymptomatic hypotension, n = 1; transient facial flush-
ing, n = 5; mild headache, n = 4). Pharmakokinetic
parameters were linear and mean elimination half-life
ranged between 14 – 20 h.
Conclusion
In patients with bivHF, oral administration of BAY 60-
4552 was well tolerated and mediated a potent vasodila-
tion. Biventricular pre- and afterload were improved,
which resulted in a significant increase in cardiac index.
These first clinical results with an oral sGC stimulator in
patients with bivHF demonstrate the potential of this new
therapeutic principle.
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Table 1: Changes in hemodynamic parameters
2.5 mg (n = 7) 7.5 mg (n = 12) 10 mg (n = 12)
PCWP [mmHg] -7.3 ± 2.8 [-28 ± 10%] -8.4 ± 3.1 [-36 ± 13%] -9.3 ± 2.5 [-43 ± 11%]
MPAP [mmHg] -8.9 ± 6.1 [-22 ± 12%] -8.0 ± 3.3 [-24 ± 9%] -7.3 ± 3.3 [-23 ± 8%]
RAP [mmHg] -3.1 ± 3.5 [-26 ± 29%] -4.3 ± 1.9 [-40 ± 15%] -4.0 ± 2.3 [-39 ± 15%]
SVR [dyn•s•cm-5] -378 ± 550 [-15 ± 21%] -523 ± 293 [-33 ± 15%] -546 ± 267 [-31 ± 12%]
CI [L/min/m2] +0.3 ± 0.3 [+17 ± 22%] +0.6 ± 0.4 [+31 ± 22%] +0.7 ± 0.5 [+33 ± 25%]
Changes from baseline (absolute and [relative] mean ± SD) of invasive hemodynamics after oral administration of 2.5, 7.5 and 10 mg BAY60-4552, p 
< 0.05 (for each change from baseline).